What we've learned from the GLP-1 explosion

How big the story actually is

By 2026, GLP-1 receptor agonists have produced one of the largest evidence portfolios in modern pharmacology. The major trial programs — STEP (semaglutide obesity), SURMOUNT (tirzepatide), SUSTAIN and SURPASS (T2D), LEADER, SUSTAIN-6, REWIND (CV outcomes), FLOW (renal outcomes), STEP-HFpEF (heart failure), SELECT (CV outcomes in obesity without diabetes), TRIUMPH (retatrutide) — collectively represent more than 100,000 randomized patient-years.

The breadth of indications established or under investigation includes type 2 diabetes, obesity, cardiovascular risk reduction, kidney disease, heart failure with preserved ejection fraction, MASH, obstructive sleep apnea, and substance-use disorders. This is a class effect of substantial scope.

The cardiovascular and renal lessons

The most striking finding of the GLP-1 era is that the same class of drugs that produces meaningful weight loss also produces independent cardiovascular and renal benefits. SELECT (semaglutide in obesity without diabetes) demonstrated 20% MACE reduction; FLOW (semaglutide in T2D + CKD) showed 24% reduction in composite kidney/CV outcomes; STEP-HFpEF demonstrated functional improvements in heart-failure with preserved ejection fraction.

The lesson generalizable to the broader peptide field is that careful pursuit of specific downstream outcomes — not just biomarker effects — is what makes a class clinically transformative. The GLP-1 trial portfolio is unusual in modern pharmacology for the breadth of hard-outcome data accumulated.

The mental-health and addiction signals

The reward-circuit effects of GLP-1 therapy are some of the most interesting findings to emerge from real-world use. The "food noise" reduction is well-documented; the alcohol-craving reduction is supported by converging preclinical, observational, and small-trial evidence; signals on smoking, gambling, and other reward-related behaviors are subject to ongoing investigation.

The 2023 European pharmacovigilance signal raising concerns about suicidal ideation triggered appropriate regulatory review, and subsequent large-cohort analyses have not confirmed a causal effect. The honest read is that the mental-health profile of the class is more complex than initially appreciated, mostly favorable, with specific concerns appropriately monitored.

The muscle-preservation question

Rapid weight loss of any cause produces fat-free mass loss. The GLP-1 era has surfaced this concern at scale, generated DEXA substudy data documenting the magnitude (~25–40% of total mass lost as lean tissue, in line with diet-alone weight loss), and motivated the next round of research questions about combination therapy with anti-myostatin / activin-receptor agents like bimagrumab.

The lesson for the broader peptide field: any intervention producing rapid weight change will produce body-composition tradeoffs that need to be characterized, not assumed away.

The access and compounding dynamics

The 2022–2025 dynamics around shortage designations, compounding pharmacy production of GLP-1s, and the FDA's evolving stance on salt-form substitutions have been a real-time stress test of the regulatory framework around compounded peptides. The lessons — about quality oversight, identity verification, dosing-error risk, and how shortage designations interact with §503A compounding — apply broadly to the rest of the peptide marketplace.

The chronic-disease framing

The most important conceptual shift of the GLP-1 era may be the framing of obesity as a chronic disease requiring chronic-disease-appropriate pharmacotherapy. STEP 4 and SURMOUNT-4 withdrawal data established that stopping GLP-1 therapy returns weight toward baseline — exactly as stopping a statin returns LDL to baseline, or stopping antihypertensives returns blood pressure to baseline. The "treatment, not cure" framing is part of how the class will be used in clinical medicine going forward.

What this teaches the broader peptide field

The GLP-1 era has demonstrated several things that the rest of the peptide therapeutic landscape will be measured against:

• Outcome-grade evidence is achievable for peptide therapeutics with sufficient development investment.
• Cardiovascular and renal benefits can be demonstrated, not just inferred from biomarkers.
• Real-world signals (mental-health effects, substance-use effects) often emerge after approval and require ongoing characterization.
• Compounded versions of approved peptides raise distinct quality and regulatory questions that the field is still working through.
• Indication expansion — from glycemic to weight to CV to renal to MASH to cognition — requires dedicated trial programs, not extrapolation.